PKCa对肝癌药物敏感性的作用

The role of PKCα in regulating multidrug resistance MDR in human hepatocellular carcinoma cell line HepG2

目的:探讨PKCa对肝癌药物敏感性的作用及在肝癌耐药中的意义。方法:利用siRNA技术,抑制HepG2细胞PKCa表达;用PMA(PKC激动剂)刺激HepG2细胞PKCa高表达,用MTT方法比较PKCa表达量的变化对HepG2细胞药物敏感性的影响。结果:经Western blotting analysis验证,siRNA对PKCa表达有显著的抑制作用;PMA刺激后PKCa呈高表达。MTT显示转染siRNA组IC50值为6.445±0.8549;用PMA处理组IC50值为11.540±1.3647。两者与对照组有显著差异性(P<0.05)。结论:肝癌细胞中,PKCa表达量的变化影响肝癌细胞对抗癌药物(表阿霉素)的敏感性。抑制PKCa表达可以增加肝癌细胞的药物敏感性。实验结果为提高肝癌综合治疗的效果提供了研究基础。

Objective：To investigate the role of protein kinase C alpha （PKCa） in regulating multidrug resistance MDR in human hepatocellular carcinoma cell line HepG2. Methods： Using siRNA technology to inhabit the expressing of PKCa ; PMA increase the expressing, MTT to test the drug sensitivity. Results： Western blotting analysis validated that the siRNA down regulated the expession of PKCa and that PMA increased the expession. MTT showed that IC50 of the siRNA group was 6. 445 ± 0. 8549 ; the PMA group was 11. 540 ± 1. 3647. Compared with the HepG2 group ,there was significant difference（ P 〈0.05 ）. Conclusion： For hepatocellular carcinoma ,the quantitative change of PKCa may influence the drug sensitivity of hepatocellular carcinoma cell. Suppression of the expression of PKCa can increase the drug sensitivity of hepatocellular carcinoma cell .